Skip to main content
SpringerLink
Log in

Clinical and pharmacoeconomic aspects both play an important role in the treatment of ovarian cancer

  • Drug economics and QOL
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bodurka-Bevers D, Sun CC, Gershenson DM. Pharmacoeconomic considerations in treating ovarian cancer. Pharmacoeconomics 2000 Feb; 17(2): 133–50

    Article  PubMed  CAS  Google Scholar 

  2. American Cancer Society. Statistics 2000: cancer facts and figures: selected cancers: ovary. Available from URL: http://www.cancer.org. Accessed on 16 Oct 2000

  3. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6

    Article  PubMed  CAS  Google Scholar 

  4. McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost-effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15(2): 640–5

    PubMed  CAS  Google Scholar 

  5. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15(2): 632–9

    PubMed  CAS  Google Scholar 

  6. Berger K, Fischer T, Szucs TD. Cost-effectiveness analysis of paclitaxel and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective. Eur J Cancer 1998; 34(12): 1894–901

    Article  PubMed  CAS  Google Scholar 

  7. Doyle C, Stockier M, Pintilie M, et al. Resource implications of palliative chemotherapy for ovarian cancer. J Clin Oncol 1997; 15(3): 1000–7

    PubMed  CAS  Google Scholar 

  8. Calhoun EA, Bennett CL. Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol 1999; 26(2 Suppl. 7): 102–7

    PubMed  CAS  Google Scholar 

  9. Patnaik A, Doyle C, Oza AM. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost. Anticancer Drugs 1998; 9: 869–78

    Article  PubMed  CAS  Google Scholar 

  10. Ortega A, Dranitsaris G, Sturgen J, et al. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66(3): 454–63

    Article  PubMed  CAS  Google Scholar 

  11. Kornblith AB, Thaler HT, Wong G, et al. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59(2): 231–42

    Article  PubMed  CAS  Google Scholar 

  12. Portenoy FK, Kornblith AB, Wong G, et al. Pain in ovarian cancer patients: prevalence, characteristics, and associated symptoms. Cancer 1994; 74: 907–15

    Article  PubMed  CAS  Google Scholar 

  13. Guidozzi F. Living with ovarian cancer. Gynecol Oncol 1993; 50: 202–7

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clinical and pharmacoeconomic aspects both play an important role in the treatment of ovarian cancer. Drugs Ther. Perspect 17, 12–15 (2001). https://doi.org/10.2165/00042310-200117120-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200117120-00004

Keywords

Search

Navigation